Guiyang TCM company puts power of technology

A panoramic view of Guizhou Zhongke Molecular Biology Co. [Photo/Guiyang news network]

Injecting the power of technology into traditional Chinese medicine (TCM) agricultural bases is a strategy utilized by Guizhou Zhongke Molecular Biology Co.

In 2021, the company settled in Nanming district of Guiyang, capital city of Southwest China's Guizhou province. It officially began operating in 2023.

Relying on PLEESIT Plant Molecular Directional Purification technology, the company has experienced rapid growth in just over a year. In 2023, the company achieved a sales revenue of 30 million yuan ($4.16 million). Sales revenue reached 8 million yuan in the first quarter of 2024, with an expectation for sales to reach 50 million yuan by the end of the year.

"TCM processing once involved unstable processing time and water ratio during boiling. However, PLEESIT technology is different. The technology uses pure water as the only medium, allowing medicinal materials to retain their original nutrients under constant low temperature, which is more conducive to be absorbed by humans," said Xia Wenjiang, deputy general manager of the company.

According to Zhang Gang, general manager of the company's national marketing center, in 2023, the company completed the upgrade and transformation of its Industry 4.0 smart unmanned factory. Only two to three workers are needed to monitor multiple production links, control various processes, and observe indicators during the production process.

Zhang introduces the company's fifth-generation technology refining products to clients. [Photo/Guiyang news network]

In March 2023, the company established high-quality raw material supply throughout Guizhou, and has deployed many technical personnel.

Xia said, "It is the continuous innovation of these experienced technical personnel that enables the company to stand out in the fiercely competitive market."